#Bexsero (4CMenB) receives positive Committee for Medicinal Products for Human Use (CHMP) of the 🇪🇺EMA opinion for one-dose Meningitis B booster for 10+ year olds
📌Recommendation based on data showing immune memory established following vaccination in infancy can be boosted up to 19 years later
📌 Once approved, the single-dose booster could help vaccination programmes maintain protection into adolescence, when disease incidence reaches a second peak
https://www.gsk.com/media/b4lh5ndm/bexsero-1-dose-booster-chmp-sea.pdf
You must log in or register to comment.